Compare JPMorgan Chase & Co (JPM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Recursion Pharmaceuticals Inc — how do they compare? JPMorgan Chase & Co trades at $344.68 (market cap $900.78B), while Recursion Pharmaceuticals Inc trades at $3.06 (market cap $1.53B). The key difference: JPMorgan Chase & Co is far larger — about 588.7× Recursion Pharmaceuticals Inc's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| JPM | RXRX | |
|---|---|---|
Market Cap | $900.78B | $1.53B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $6.79 |
52-Week Low | $282.84 | $2.84 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $345.10, up 1.17% on the day, with strong technical momentum as the stock approaches resistance at $347. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growing to $181.85 billion in 2025. Analyst sentiment remains positive with a consensus price target of $372.73, representing 8% upside potential from current levels.
JPMorgan demonstrates solid fundamentals with a reasonable P/E of 14.52 and strong net income margin of 33.4%. However, negative operating cash flow of -$147.78 billion in 2025 and geopolitical risks highlighted by CEO Jamie Dimon present headwinds. The stock offers value for long-term investors but faces near-term volatility from earnings uncertainty and macroeconomic concerns.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
